EP0951296A1 - NEUARTIGE POLYPEPTIDEN FtsL - Google Patents

NEUARTIGE POLYPEPTIDEN FtsL

Info

Publication number
EP0951296A1
EP0951296A1 EP97937305A EP97937305A EP0951296A1 EP 0951296 A1 EP0951296 A1 EP 0951296A1 EP 97937305 A EP97937305 A EP 97937305A EP 97937305 A EP97937305 A EP 97937305A EP 0951296 A1 EP0951296 A1 EP 0951296A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
polynucleotide
ftsl
compnsmg
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97937305A
Other languages
English (en)
French (fr)
Inventor
John Edward Hodgson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Hodgson John Edward
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616312.6A external-priority patent/GB9616312D0/en
Application filed by Hodgson John Edward, SmithKline Beecham Corp filed Critical Hodgson John Edward
Publication of EP0951296A1 publication Critical patent/EP0951296A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses.
  • the invention relates to novel polynucleondes and polypeptides of the penicillin binding protein family, hereinafter referred to as "FtsL”.
  • Staphylococcal genes and gene products are particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics.
  • the Staphylococci make up a medically important genera of microbes. T ey are known to produce two types of disease, invasive and toxigenic. Invasive infections are characte ⁇ zed generally by abscess formation effecting both skin surfaces and deep tissues. S. aureus is the second leading cause of bacteremia in cancer patients Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacte ⁇ al endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxms as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome
  • Staphylococcus aureus infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new anti-microbial agents and diagnostic tests for this organism.
  • FtsL is a membrane bound protein involved in bactenal cell division. FtsL is essential for cell growth and division. An ftsL null mutation results in inhibition of cell division, the formation of long, non-septate filaments, and ultimately cessation of growth and lysis (Guzman, L-M., Barondess, J. J., and Beckwith, J. (1992) J. Bacte ⁇ ol 174 : 7716-7728)
  • Penicilhn-bmdmg protein 3 a membrane protein specifically required during septation (Ishmo, F.,
  • FtsL is also a cytoplasmic membrane protein with a cytoplasmic N-terminus, a membrane-spanning segment, and a penplasmic carboxy terminus.
  • polypeptides of the invention have amino acid sequence homology to a known Bacillus subtihs FtsL protein.
  • the polynucleotide comp ⁇ ses a region encodmg FtsL polypeptides comprising the sequence set out in Table 1 [SEQ LD NO 1] which includes a full length gene, or a vanant thereof.
  • an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 strain contained in the deposited strain
  • a further aspect of the invention there are provided isolated nucleic acid molecules encoding FtsL, particularly Staphylococcus aureus FtsL, including mRNAs, cDNAs, genomic
  • DNAs Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful va ⁇ ants thereof, and compositions comp ⁇ smg the same.
  • a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization
  • particularly preferred embodiments of the invention are naturally occurring allehc vanants of FtsL and polypeptides encoded thereby
  • FtsL novel polypeptides of Staphylococcus aureus referred to herein as FtsL as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful vanants thereof, and composmons comp ⁇ sing the same
  • va ⁇ ants of FtsL polypeptide encoded by naturally occurring alleles of the FtsL gene are va ⁇ ants of FtsL polypeptide encoded by naturally occurring alleles of the FtsL gene.
  • FtsL polypeptides useful as antibactenal agents, including, for example, antibodies
  • products, compositions and methods for assessing FtsL expression treating disease, for example, disease, such as, infections of the upper respiratory tract (e g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g , infective endocarditis), gastrointestinal (e.g , secretory diarrhoea, splenic absces, retrope ⁇ toneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepha ⁇ tis, conjunctivitis, keratiti
  • atitis media e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis
  • lower respiratory e.g., empyema, lung
  • polynucleotides that hyb ⁇ dize to FtsL polynucleotide sequences, particularly under stnngent conditions.
  • methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comp ⁇ smg: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound, such binding or interaction being associated with a second component capable of providing a detectable signal m response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determinmg whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of the compound with the polypeptide or polynucleotide.
  • FtsL agonists and antagonists preferably bacte ⁇ ostatic or bacte ⁇ ocidal agonists and antagonists.
  • compositions compnsing a FtsL polynucleotide or a FtsL polypeptide for administration to a cell or to a multicellular organism preferably bacte ⁇ ostatic or bacte ⁇ ocidal agonists and antagonists.
  • “Host cell” is a cell which has been transformed or transfected, or is capable of transformation or transfection by an exogenous polynucleotide sequence.
  • Identity is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between stnngs of such sequences.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and simila ⁇ ty are codified m publicly available computer programs Preferred computer program methods to determine identity and similanty between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., J. Molec. Biol. 215.
  • BLAST X program is publicly available from NCBI and other sources ⁇ BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894, Altschul, S , et al , J Mol Biol 215 403-410 (1990)
  • a polynucleotide having a nucleotide sequence having at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1.
  • a polynucleotide having a nucleotide sequence at least 95% identical to a reference nucleotide sequence up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides m the reference sequence may be inserted into the reference sequence
  • These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides m the reference sequence or in one or more contiguous groups within the reference sequence.
  • a polypeptide having an ammo acid sequence having at least, for example, 95% identity to a reference amino acid sequence of SEQ ID NO 2 is intended that the amino acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the reference amino acid of SEQ LD NO 2
  • up to 5% of the ammo acid residues in the reference sequence may be deleted or substituted with another ammo acid, or a number of amino acids up to 5% of the total ammo acid residues m the reference sequence may be inserted into the reference sequence.
  • These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference ammo acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or m one or more contiguous groups within the reference sequence
  • Isolated means altered “by the hand of man” from its natural state, i e , if it occurs m nature, it has been changed or removed from its o ⁇ ginal environment, or both.
  • a polynucleonde or a polypeptide naturally present in a living organism is not “isolated,” but the same polynucleotide or polypeptide separated from the coexisting mate ⁇ als of its natural state is “isolated" as the term is employed herein
  • Polynucleot ⁇ de(s) generally refers to any poly ⁇ bonucleotide or polydeox ⁇ bonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
  • Polynucleot ⁇ de(s) include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions or single-, double- and tnple-stranded regions, single- and double- stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or, more typically, double-stranded, or tnple-stranded regions, or a mixture of single- and double-stranded regions.
  • polynucleotide refers to tnple-stranded regions comp ⁇ smg RNA or DNA or both RNA and DNA.
  • the strands m such regions may be from the same molecule or from different molecules.
  • the regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules.
  • One of the molecules of a t ⁇ ple-helical region often is an ohgonucleotide.
  • polynucleot ⁇ de(s) also includes DNAs or RNAs as descnbed above that contain one or more modified bases
  • DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleot ⁇ de(s)” as that term is intended herein
  • DNAs or RNAs compnsmg unusual bases, such as inosine, or modified bases, such as t ⁇ tylated bases, to name just two examples are polynucleotides as the term is used herein. It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art.
  • polynucleot ⁇ de(s) as it is employed herein embraces such chemically, enzymatically or metabolicaily modified forms of polynucleotides, as well as the chemical forms of DNA and RNA characte ⁇ stic of viruses and cells, including, for example, simple and complex cells. "Polynucleot ⁇ de(s)” also embraces short polynucleotides often referred to as ohgonucleot ⁇ de(s).
  • Polypept ⁇ de(s) refers to any peptide or protein compnsmg two or more ammo acids joined to each other by peptide bonds or modified peptide bonds. "Polypept ⁇ de(s)” refers to both short chains, commonly referred to as peptides, o gopeptides and oligomers and to longer chains generally referred to as proteins. Polypeptides may contain ammo acids other than the 20 gene encoded amino acids. “Polypept ⁇ de(s)” include those modified either by natural processes, such as processing and other post-translational modifications, but also by chemical modification techniques.
  • Modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide de ⁇ vative, covalent attachment of a lipid or lipid de ⁇ vative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, lodination, methylation, mynstoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP- ⁇
  • Polypeptides may be branched or cyclic, with or without branching. Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well.
  • Variant(s) is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential prope ⁇ ies.
  • a typical vanant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the vanant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in ammo acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below.
  • a typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical.
  • a variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination.
  • a substituted or inserted amino acid residue may or may not be one encoded by the genetic code.
  • a variant of a polynucleotide or polypeptide may be a naturally occumng such as an allelic variant, or it may be a variant that is not known to occur naturally. Non- naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques, by direct synthesis, and by other recombinant methods known to skilled artisans.
  • the invention relates to novel FtsL polypeptides and polynucleotides as described in greater detail below.
  • the invention relates to polypeptides and polynucleotides of a novel FtsL of Staphylococcus aureus, which is related by ammo acid sequence homology to Bacillus subtilis FtsL polypeptide.
  • the invention relates especially to FtsL having the nucleotide and ammo acid sequences set out in Table 1 [SEQ LD NO: 1] and Table 1 [SEQ ID NO: 2] respectively, and to the FtsL nucleotide sequences of the DNA in the deposited strain and amino acid sequences encoded thereby.
  • a deposit containing a Staphylococcus aureus WCUH 29 strain has been deposited with the National Collections of Industnal and Ma ⁇ ne Bacte ⁇ a Ltd. (herein "NCIMB"), 23 St Machar Dnve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771, and is referred to as Staphylococcus aureus WCUH29 on deposit
  • the Staphylococcus aureus strain deposit is referred to herein as "the deposited strain” or as "the DNA of the deposited strain.”
  • the deposited strain contains the full length FtsL gene.
  • the sequence of the polynucleotides contained in the deposited strain, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling in the event of any conflict with any descnption of sequences herein.
  • the deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The strain will be irrevocably and without restnction or condition released to the public upon the issuance of a patent
  • the deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. ⁇ 112
  • a license may be required to make, use or sell the deposited strain, and compounds de ⁇ ved therefrom, and no such license is hereby granted Polypeptides
  • polypeptides of the invention include the polypeptide of Table 1 [SEQ ID NO 2] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of FtsL, and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ED NOS:2 and 4] or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NOS.2 and 4], and more preferably at least 90% simila ⁇ ty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NOS.2 and 4] and still more preferably at least 95% simila ⁇ ty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ED NOS:2 and 4] and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 amino acids
  • the invention also includes polypeptides of the formula set forth in Table 1 (D) [SEQ LD
  • X is hydrogen
  • Y is hydrogen or a metal
  • R ⁇ and R2 is any ammo acid residue
  • n is an integer between 1 and
  • Any stretch of ammo acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer.
  • a fragment is a vanant polypeptide having an ammo acid sequence that entirely is the same as part but not all of the amino acid sequence of the aforementioned polypeptides
  • FtsL polypeptides fragments may be "free-standing,” or comp ⁇ sed within a larger polypeptide of which they form a part or region, most preferably as a single continuous region, a single larger polypeptide.
  • Preferred fragments include, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NOS:2 and 4], or of va ⁇ ants thereof, such as a continuous senes of residues that includes the ammo terminus, or a continuous senes of residues that includes the carboxyl terminus.
  • Degradation forms of the polypeptides of the invention in a host cell, particularly a Staphylococcus aureus are also preferred.
  • fragments characte ⁇ zed by structural or functional attributes such as fragments that compnse alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn- forming regions, coil and coil-forming regions, hydrophi c regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.
  • biologically active fragments which are those fragments that mediate activities of FtsL, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Also included are those fragments that are antigenic or lmmunogenic in an animal, especially in a human. Particularly preferred are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease in an individual, particularly a human.
  • Va ⁇ ants that are fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these vanants may be employed as intermediates for producing the full-length polypeptides of the invention.
  • Another aspect of the invention relates to isolated polynucleotides, including the full length gene, that encode the FtsL polypeptide having a deduced amino acid sequence of Table 1 [SEQ ID NOS:2 and 4] and polynucleotides closely related thereto and va ⁇ ants thereof.
  • Table 1 [SEQ ID NOS:2 and 4]
  • polynucleotides closely related thereto and va ⁇ ants thereof Using the information provided herein, such as a polynucleotide sequence set out m Table
  • a polynucleotide of the invention encoding FtsL polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacte ⁇ a using Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone.
  • standard cloning and screening methods such as those for cloning and sequencing chromosomal DNA fragments from bacte ⁇ a using Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone.
  • a polynucleotide sequence of the invention such as a sequence given in Table 1 [SEQ ID NOS.
  • a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 in E coli or some other suitable host is probed with a radiolabeled ohgonucleotide, preferably a 17-mer or longer, derived from a partial sequence.
  • Clones carrying DNA identical to that of the probe can then be distinguished using stnngent conditions.
  • sequencing primers designed from the ongmal sequence it is then possible to extend the sequence m both directions to determine the full gene sequence. Conveniently, such sequencing is performed using denatured double stranded DNA prepared from a plasmid clone.
  • the DNA sequence set out m Table 1 [SEQ ED NOS:l] contains an open reading frame encoding a protein having about the number of ammo acid residues set forth in Table 1 [SEQ ID NO:2] with a deduced molecular weight that can be calculated using ammo acid residue molecular weight values well known in the art.
  • the polynucleotide of SEQ D NO. 1, between nucleotide number 1 through number 399 encodes the polypeptide of SEQ ED NO:2
  • FtsL of the invention is structurally related to other proteins of the penicillin binding protein family, as shown by the results of sequencing the DNA encoding FtsL of the deposited strain.
  • the protein exhibits greatest homology to Bacillus subtilis FtsL protein among known
  • the invention provides a polynucleotide sequence identical over its entire length to the coding sequence in Table 1 [SEQ ID NO 1] Also provided by the invention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment in reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence
  • the polynucleotide may also contain non-coding sequences, including for example, but not limited to non-codmg 5' and 3' sequences, such as the transcnbed, non-translated sequences, termination signals, ⁇ bosome binding sites, sequences that stabilize mRNA, introns, polyadenylation signals, and additional coding sequence which encode additional ammo acids
  • a marker sequence that facilitates punfication of the fused polypeptide can be encoded
  • the marker sequence is a hexa-histidine
  • Polynucleotides of the invention also include, but are not limited to, polynucleotides compnsmg a structural gene and its naturally associated sequences that control gene expression
  • a preferred embodiment of the invention is a polynucleotide of compnsmg nucleotide 1 to 399 set forth in SEQ ED NO: 1 of Table 1 which encode the FtsL polypeptide
  • the invention also includes polynucleotides of the formula set forth in Table 1 (C)[SEQ ED NO 1] wherein, at the 5' end of the molecule, X is hydrogen, and at the 3 1 end of the molecule, Y is hydrogen or a metal, Rj and R2 is any nucleic acid residue, and n is an mteger between 1 and 1000. Any stretch of nucleic acid residues denoted by either R group, where R is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer
  • polynucleotide encoding a polypeptide encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus FtsL having the ammo acid sequence set out in Table 1 [SEQ ED NO.2]
  • the term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the
  • polypeptide for example, interrupted by integrated phage or an insertion sequence or editing
  • additional regions that also may contain coding and/or non-coding sequences
  • the invention further relates to va ⁇ ants of the polynucleotides descnbed herein that encode for vanants of the polypeptide having the deduced ammo acid sequence of Table 1 [SEQ ED NO.2]. Vanants that are fragments of the polynucleotides of the invention may be used to synthesize full-length polynucleotides of the invention.
  • polynucleotides encoding FtsL vanants that have the am o acid sequence of FtsL polypeptide of Table 1 [SEQ ED NO 2] in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no ammo acid residues are substituted, deleted or added, in any combination.
  • silent substitutions, additions and deletions that do not alter the properties and activities of FtsL.
  • polynucleotides that are at least 70% identical over their entire length to a polynucleotide encoding FtsL polypeptide having an amino acid sequence set out m Table 1 [SEQ ID NOS:2 and 4], and polynucleotides that are complementary to such polynucleotides.
  • polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encoding FtsL polypeptide of the deposited strain and polynucleotides complementary thereto
  • polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred.
  • those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred
  • Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by the DNA of Table 1 [SEQ ED NO:l],
  • the invention further relates to polynucleotides that hybndize to the herem above- descnbed sequences.
  • the invention especially relates to polynucleotides that hybndize under st ⁇ ngent conditions to the herein above-descnbed polynucleotides.
  • st ⁇ ngent conditions and “stnngent hyb ⁇ dization conditions” mean hyb ⁇ dization will occur only if there is at least 95% and preferably at least 97% identity between the sequences
  • An example of st ⁇ ngent hyb ⁇ dization conditions is overnight incubation at 42°C in a solution compnsmg 50% formamide, 5x SSC (150mM NaCl, 15mM tnsodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing the hyb ⁇ dization support in 0 lx SSC at about 65°C Hybndization and wash conditions are well known and exemplified in Sambrook, et al., Molecular Cloning A Laboratory Manual, Second Edition, Cold Spnng Harbor, N Y., (19
  • the invention also provides a polynucleotide consisting essentially of a polynucleotide sequence obtainable by screening an appropnate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:l or SEQ ID NO.3 under st ⁇ ngent hyb ⁇ dization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:l or a fragment thereof; and isolating said DNA sequence.
  • Fragments useful for obtaining such a polynucleotide include, for example, probes and pnmers descnbed elsewhere herein.
  • polynucleotide assays of the invention may be used as a hybndization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding FtsL and to isolate cDNA and genomic clones of other genes that have a high sequence simila ⁇ ty to the FtsL gene
  • probes generally will compnse at least 15 bases
  • such probes will have at least 30 bases and may have at least 50 bases.
  • Particularly preferred probes will have at least 30 bases and will have 50 bases or less.
  • the coding region of the FtsL gene may be isolated by screening using the DNA sequence provided in SEQ ED NO: 1 to synthesize an oligonucleotide probe.
  • a labeled ohgonucleotide having a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hyb ⁇ dizes to.
  • polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to polynucleotide assays
  • Polynucleotides of the invention that are o gonucleotides de ⁇ ved from the sequences of SEQ ID NOS: 1 and/or 2 may be used in the processes herein as descnbed, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are
  • the invention also provides polynucleotides that may encode a polypeptide that is the mature protein plus additional ammo or carboxyl-terminal amino acids, or amino acids intenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance).
  • Such sequences may play a role m processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things
  • the additional amino acids may be processed away from the mature protein by cellular enzymes.
  • a precursor protein, having the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors generally are activated Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.
  • a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotem, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed du ⁇ ng processing steps that produce active and mature forms of the polypeptide
  • the invention also relates to vectors that comp ⁇ se a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.
  • Cell-free translation systems can also be employed to produce such proteins using RNAs de ⁇ ved from the DNA constructs of the invention.
  • host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention.
  • Introduction of a polynucleotide mto the host cell can be effected by methods descnbed in many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al., MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed., Cold
  • encoding for polypeptides of the invention include, among others, chromosomal, episomal and virus-denved vectors,
  • the expression system constructs may contain control regions that regulate as well as engender expression
  • any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard.
  • the appropnate DNA sequence may be inserted into the expression system by any of a vanety of well-known and routine techniques, such as, for example, those set forth in Sambrook et al , MOLECULAR CLONING, A LABORATORY MANUAL, (supra).
  • appropnate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be heterologous signals.
  • Polypeptides of the invention can be recovered and pu ⁇ fied from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Most preferably, high performance liquid
  • t l chromatography is employed for pu ⁇ fication.
  • Well known techniques for refolding protein may be employed to regenerate active conformation when the polypeptide is denatured dunng isolation and or punfication.
  • Diagnostic Assays This invention is also related to the use of the FtsL polynucleotides of the invention for use as diagnostic reagents. Detection of FtsL in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease.
  • Eukaryotes particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism compnsmg the FtsL gene may be detected at the nucleic acid level by a vanety of techniques.
  • Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin. Genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification technique p ⁇ or to analysis. RNA or cDNA may also be used in the same ways. Using amplification, charactenzation of the species and strain of prokaryote present in an individual, may be made by an analysis of the genotype of the prokaryote gene.
  • Deletions and insertions can be detected by a change in size of the amplified product m compa ⁇ son to the genotype of a reference sequence
  • Point mutations can be identified by hyb ⁇ dizing amplified DNA to labeled FtsL polynucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denatunng agents, or by direct DNA sequencing. See, e.g , Myers et al., Science, 230 1242 (1985).
  • Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method. See, e.g , Cotton et al., Proc Natl. Acad. Sci., USA, 85. 4397-4401 (1985).
  • RNA or cDNA may also be detected at the DNA level by a vanety of techniques, to allow for serotypmg, for example.
  • RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan.
  • RNA or cDNA may also be detected at the DNA level by a vanety of techniques, to allow for serotypmg, for example.
  • RT-PCR can be used to detect mutations. It is particularly preferred to used RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan.
  • PCR pnmers complementary to a nucleic acid encoding FtsL can be used to identify and analyze mutations.
  • the invention further provides these pnmers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end.
  • These pnmers may be used for, among other things, amplifying FtsL DNA isolated from a sample derived from an individual.
  • the pnmers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to vanous techniques for elucidation of the DNA sequence. In this way, mutations m the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent.
  • the invention further provides a process for diagnosing, disease, preferably bactenal infections, more preferably infections by Staphylococcus aureus, and most preferably disease, such as, infections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepharitis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and urinary tract (e.g., epididymitis, intrarenal and penneph ⁇ c absces
  • Increased or decreased expression of FtsL polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting and other hyb ⁇ dization methods.
  • a diagnostic assay in accordance with the invention for detecting over- expression of FtsL protein compared to normal control tissue samples may be used to detect the presence of an infection, for example.
  • Assay techniques that can be used to determine levels of a FtsL protein, in a sample de ⁇ ved from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.
  • polypeptides of the invention or va ⁇ ants thereof, or cells expressing them can be used as an lmmunogen to produce antibodies lmmunospecific for such polypeptides
  • Antibodies as used herein includes monoclonal and polyclonal antibodies, chime ⁇ c, single chain, simia zed antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobu n expression library.
  • Antibodies generated against the polypeptides of the invention can be obtained by admimstenng the polypeptides or epitope-bea ⁇ ng fragments, analogues or cells to an animal, preferably a nonhuman, using routine protocols.
  • any technique known m the art that provides antibodies produced by continuous cell line cultures can be used. Examples include vanous techniques, such as those in Kohler, G. and Milstein, C, Nature 256 495-497 (1975); Kozbor et al , Immunology Today 4 72 (1983), Cole et al , pg 77- 96 in MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc (1985)
  • phage display technology may be utilized to select antibody genes with binding activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti-FtsL or from naive hbra ⁇ es (McCafferty, J. et al., (1990), Nature 348, 552-554; Marks, J. et al., (1992) Biotechnology 10, 779-783).
  • the affinity of these antibodies can also be improved by chain shuffling (Clackson, T. et al., (1991) Nature 352, 624-628).
  • each domain may be directed against a different epitope - termed 'bispecific' antibodies
  • the above-descnbed antibodies may be employed to isolate or to identify clones expressing the polypeptides to punfy the polypeptides by affinity chromatography.
  • antibodies against FtsL- polypeptide may be employed to treat infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e.g., empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal infections, particularly bactenal infections and especially disease, such as, mfections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis
  • CNS e.g., cerebral abscess
  • Polypeptide variants include antigenically, epitopically or immunologically equivalent vanants that form a particular aspect of this invention.
  • antigenically equivalent denvative encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host.
  • immunologically equivalent de ⁇ vative encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the immediate physical interaction between pathogen and mammalian host.
  • the polypeptide such as an antigenically or immunologically equivalent denvative or a fusion protein thereof is used as an antigen to immunize a mouse or other animal such as a rat or chicken.
  • the fusion protein may provide stability to the polypeptide
  • the antigen may be associated, for example by conjugation, with an immunoge c earner protein for example bovine serum albumin (BSA) or keyhole limpet haemocyan (KLH).
  • BSA bovine serum albumin
  • KLH keyhole limpet haemocyan
  • a multiple antigenic peptide compnsmg multiple copies of the protein or polypeptide, or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigenic to improve lmmunogemcity so as to obviate the use of a earner.
  • the antibody or vanant thereof is modified to make it less immunogemc m the individual.
  • the antibody may most preferably be "humanized", where the complimenta ⁇ ty determining reg ⁇ on(s) of the hyb ⁇ doma-de ⁇ ved antibody has been transplanted into a human monoclonal antibody , for example as described in Jones, P. et al. (1986), Nature 321, 522-525 or Tempest et al., (1991) Biotechnology 9, 266- 273.
  • a polynucleotide of the invention m genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff et al , Hum Mol Genet 1992, 1:363, Manthorpe et al, Hum. Gene Ther. 1963-4, 419), delivery of DNA complexed with specific protein earners (Wu et al , J Biol Chem 1989-
  • Polypeptides of the invention may also be used to assess the binding of small molecule substrates and hgands in, for example, cells, cell-free preparations, chemical branes, and natural product mixtures.
  • substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, e g , Coligan et al , Current Protocols in Immunology 1(2) Chapter s (1991)
  • the invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of FtsL polypeptides or polynucleotides, particularly those compounds that are bacte ⁇ ostatic and/or bactenocidal
  • the method of screening may involve high-throughput techniques.
  • a synthetic reaction mix for example, a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg FtsL polypeptide and a labeled substrate or ligand of such polypeptide is incubated m the absence or the presence of a candidate molecule that may be a FtsL agonist or antagonist
  • the ability of the candidate molecule to agonize or antagonize the FtsL polypeptide is reflected in decreased bindmg of the labeled ligand or decreased production of product from such substrate.
  • Molecules that bind gratuitously, i e , without inducing the effects of FtsL polypeptide are most likely to be good antagonists
  • Molecules that bind well and increase the rate of product production from substrate are agonists. Detection of the rate or level of production of product from substrate may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colonmet ⁇ c labeled substrate converted into product, a reporter gene that is responsive to changes in FtsL polynucleotide or polypeptide activity, and binding assays known m the art
  • Another example of an assay for FtsL antagonists is a competitive assay that combines
  • FtsL and a potential antagonist with FtsL-bmd g molecules, recombinant FtsL binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropnate conditions for a competitive inhibition assay FtsL can be labeled, such as by radioactivity or a
  • Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide or polypeptide of the invention and thereby inhibit or extinguish its activity
  • Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing FtsL-induced activities, thereby preventing the action of FtsL by excluding FtsL from binding
  • Potential antagonists mclude a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented.
  • small molecules include but are not limited to small organic molecules, peptides or peptide- ke molecules.
  • Other potential antagonists mclude antisense molecules (see Okano, J Neurochem 56. 560 (1991), OUGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press, Boca Raton, FL ( 1988), for a descnption of these molecules)
  • Preferred potential antagonists include compounds related to and va ⁇ ants of FtsL
  • Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds.
  • the encoded protein upon expression, can be used as a target for the screening of antibacterial drugs Additionally, the DNA sequences encoding the ammo terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.
  • the invention also provides the use of the polypeptide, polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection.
  • the molecules of the invention may be used: in the prevention of adhesion of bactena, in particular gram positive bacteria, to mammalian extracellular mat ⁇ x proteins on m-dwelling devices or to extracellular mat ⁇ x proteins in wounds, to block FtsL protem-mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kmases (Rosenshine et al , Infect Immun 60 221 1 (1992), to block bacterial adhesion between mammalian extracellular mat ⁇ x
  • the antagonists and agonists of the invention may be employed, for instance, to inhibit and treat disease, such as, infections of the upper respiratory tract (e.g., otitis media, bactenal tracheitis, acute epiglottitis, thyroiditis), lower respiratory (e g , empyema, lung abscess), cardiac (e.g., infective endocarditis), gastrointestinal (e.g., secretory diarrhoea, splenic absces, retropentoneal abscess), CNS (e.g., cerebral abscess), eye (e.g., blepha ⁇ tis, conjunctivitis, keratitis, endophthalmitis, preseptal and orbital celluhtis, darcryocystitis), kidney and u ⁇ nary tract (e.g., epididymitis, mtrarenal and pe ⁇ neph ⁇ c absces, toxic shock syndrome), skm (e.g
  • H pylori Helicobacter pylori bacteria infect the stomachs of over one-third of the world's population causing stomach cancer, ulcers, and gast ⁇ tis
  • International Agency for Research on Cancer (1994) Schistosomes, Liver Flukes and Helicobacter Pylon International Agency for Research on Cancer, Lyon, France; http://www.uicc.ch/ecp/ecp2904.htm).
  • the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H. pylori and gast ⁇ c adenocarcmoma, classifying the bacte ⁇ um as a Group I (definite) carcinogen.
  • Preferred antimicrobial compounds of the invention (agonists and antagonists of FtsL) found using screens provided by the invention, particularly broad- spectrum antibiotics, should be useful in the treatment of H. pylori infection Such treatment should decrease the advent of H. cancers, such as gastrointestinal carcinoma. Such treatment should also cure gast ⁇ c ulcers and gast ⁇ tis.
  • Vaccines Another aspect of the invention relates to a method for inducing an immunological response m an individual, particularly a mammal which compnses inoculating the individual with FtsL, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bactenal infection and most particularly Staphylococcus aureus infection. Also provided are methods whereby such immunological response slows bactenal replication.
  • Yet another aspect of the invention relates to a method of inducing immunological response in an individual which compnses dehve ⁇ ng
  • nucleic acid vector to direct expression of FtsL, or a fragment or a variant thereof, for expressing FtsL, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not.
  • an immunological response such as, to produce antibody and or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not.
  • One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.
  • nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or a DNA/RNA hybrid.
  • a further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to a FtsL or protein coded therefrom, wherein the composition comprises a recombinant FtsL or protein coded therefrom compnsing DNA which codes for and expresses an antigen of said FtsL or protein coded therefrom.
  • the immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.
  • a FtsL polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties.
  • fused recombinant protein preferably further comprises an antigenic co-protein, such as lipoprotein D from Hemophilus influenzae, Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-protems which solubilize the protein and facilitate production and purification thereof.
  • the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system.
  • the co-protein may be attached to either the ammo or carboxy terminus of the first protein.
  • compositions particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273: 352 (1996). Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of
  • the polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacte ⁇ a, for example by blocking adherence of bacteria to damaged tissue.
  • tissue damage include wounds m skm or connective tissue caused, e.g., by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagma.
  • the invention also includes a vaccine formulation which compnses an immunogemc recombinant protein of the invention together with a suitable earner.
  • the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or mtradermal.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous stenle injection solutions which may contain anti-oxidants, buffers, bactenostats and solutes which render the formulation lnsoto c with the bodily fluid, preferably the blood, of the individual, and aqueous and non-aqueous ste ⁇ le suspensions which may include suspending agents or thickening agents
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-d ⁇ ed condition requinng only the addition of the stenle liquid earner immediately pnor to use.
  • the vaccine formulation may also include adjuvant systems for enhancing the lmmunogenicity of the formulation, such as oil-in water systems and other systems known in the
  • compositions for purposes of compositions, kits and administration
  • the invention also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagonists
  • the polypeptides of the invention may be employed m combination with a non-ste ⁇ le or ste ⁇ le earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for administration to a subject.
  • Such compositions compnse for instance, a media additive or a therapeutically effective amount of a polypeptide of the invention and a pharmaceutically acceptable earner or excipient
  • Such earners may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.
  • the formulation should suit the mode of administration
  • the invention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention
  • Polypeptides and other compounds of the invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.
  • compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intrapentoneal, intramuscular, subcutaneous, mtranasal or mtradermal routes among others
  • the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isoto c
  • the composition may be formulated for topical application for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropnate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams.
  • Such topical formulations may also contain compatible conventional earners, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions.
  • Such earners may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation
  • the daily dosage level of the active agent will be from 0 01 mg kg to 10 mg/kg, typically around 1 mg/kg.
  • the physician m any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual.
  • the above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are mented, and such are within the scope of this invention.
  • In-dwelling devices include surgical implants, prosthetic devices and catheters, i.e., devices that are introduced to the body of an individual and remain in position for an extended time.
  • Such devices include, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrosp al fluid shunts, unnary catheters, continuous ambulatory pentoneal dialysis (CAPD) catheters.
  • CAPD continuous ambulatory pentoneal dialysis
  • composition of the invention may be administered by injection to achieve a systemic effect against relevant bacte ⁇ a shortly before insertion of an in-dwelling device. Treatment may be continued after surgery during the m-body time of the device.
  • the composition could also be used to broaden pe ⁇ operative cover for any surgical technique to prevent bactenal wound infections, especially Staphylococcus aureus wound infections.
  • compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bactena to matnx proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.
  • the composition of the invention may be used to bathe an indwelling device immediately before insertion.
  • the active agent will preferably be present at a concentration of l ⁇ g/ml to lOmg/ml for bathing of wounds or indwelling devices
  • a vaccine composition is conveniently in mjectable form. Conventional adjuvants may be employed to enhance the immune response
  • a suitable unit dose for vaccination is 0 5-5 microgram kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals.
  • Example 1 Strain selection, Library Production and Sequencing The polynucleotide having the DNA sequence given in SEQ ED NO: l was obtained from a library of clones of chromosomal DNA of Staphylococcus aureus in E. coli. The sequencing data from two or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO: l. Libraries may be prepared by routine methods, for example: Methods 1 and 2 below.
  • Total cellular DNA is mechanically sheared by passage through a needle in order to size-fractionate according to standard procedures.
  • DNA fragments of up to 1 lkbp in size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added. Fragments are ligated into the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E.coli infected with the packaged library.
  • the library is amplified by standard procedures.
  • Total cellular DNA is partially hydrolyzed with a one or a combination of rest ⁇ ction enzymes appropnate to generate a series of fragments for cloning into library vectors (e.g., Rsal, Pall, Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures.
  • library vectors e.g., Rsal, Pall, Alul, Bshl235I
  • EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI, the library packaged by standard procedures, and E.coli infected with the packaged library.
  • the library is amplified by standard procedures.
  • ADDRESSEE Dechert Price & Rhoads
EP97937305A 1996-08-02 1997-08-01 NEUARTIGE POLYPEPTIDEN FtsL Withdrawn EP0951296A1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9616312.6A GB9616312D0 (en) 1996-08-02 1996-08-02 Novel compounds
GB9616312 1996-08-02
US2730196P 1996-10-01 1996-10-01
US27301P 1996-10-01
PCT/US1997/014492 WO1998005356A1 (en) 1996-08-02 1997-08-01 NOVEL FtsL

Publications (1)

Publication Number Publication Date
EP0951296A1 true EP0951296A1 (de) 1999-10-27

Family

ID=26309808

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97937305A Withdrawn EP0951296A1 (de) 1996-08-02 1997-08-01 NEUARTIGE POLYPEPTIDEN FtsL

Country Status (3)

Country Link
EP (1) EP0951296A1 (de)
JP (1) JP2002515748A (de)
WO (1) WO1998005356A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216119A (en) * 1985-05-13 1989-01-06 Commw Scient Ind Res Org Vaccine produced using antigens of a pseudocapsule producing strain of s.aureus
EP0875578A3 (de) * 1991-03-19 1999-05-12 Eli Lilly And Company Derivate von Penicillin-Bindungsprotein 2A aus Staphylococcus aureus Stamm 27R zur Verwendung in der Reinigung davon und Bestimmung von gegen Methicillin-resistente Mikroorganismen wirksame Verbindungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9805356A1 *

Also Published As

Publication number Publication date
WO1998005356A8 (en) 1999-09-10
JP2002515748A (ja) 2002-05-28
WO1998005356A1 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
US6348584B1 (en) Fibronectin binding protein compounds
EP0904280A1 (de) ASPARTYL-tRNS-SYNTHETASE VON STREPOCOCCUS PNEUMONIAE
US20020076766A1 (en) Novel glucosaminidase
US6586578B1 (en) Defl
EP1062225A1 (de) Replikative helicase dnab von staphylococcus aureus
US6300094B1 (en) Polynucleotides encoding a novel ABC transporter
EP0913474A2 (de) DbpA, eine Helikase aus Staphylococcus aureus
WO1998010652A1 (en) NOVEL trpS
EP1024821A1 (de) Neue prokaryotische polynukleotide und polypeptide und deren verwendung
EP0913481A2 (de) Staphylococcus aureus Mitglied der DEAD-type ATP-abhängigen RNA helicasen (dbpB)
EP0899337A2 (de) FtsY Polynukleotiden und Polypeptides von Stapyloccoccus aureus aus der Signalherkennungsproteinfamilie
EP1047770A1 (de) Histidinkinase
US6126937A (en) ClpL
EP0893502A2 (de) GreA aus Staphylococcus aureus
US6524813B1 (en) Polynucleotide encoding spo0J1 of Staphylococcus aureus
US5866368A (en) GreA
WO1998005356A1 (en) NOVEL FtsL
US6346393B1 (en) Polynucleotides encoding a ribonuclease s
EP0881285A1 (de) D-Alanin transferase
EP1068220A1 (de) Nrdf
EP0968293A1 (de) Staphylococcus 3-dehydrochinate synthase
EP1009443A1 (de) priA POLYPEPTIDE
WO1998041234A1 (en) Novel compounds
EP1071694A1 (de) Staphylococcus aureus spo0j2: polynucleotid und protein
US20020058308A1 (en) Novel greA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990303

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE DK FR GB IT LI NL

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM CORPORATION

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20020204